-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Influenza Virus
CAS No. | Product Name | Inquiry |
---|---|---|
2738526-22-0 |
Neuraminidase-IN-6Neuraminidase-IN-6 (Compound 5c) is a potent inhibitor of neuraminidase with an IC50 of 0.11 μM. Neuraminidase-IN-6 is a 1,3,4-triazole-3-acetamide derivative. Neuraminidase (NA) is an ideal target for the development of anti-influenza drugs. |
|
2739990-96-4 |
Antiviral agent 43 |
|
2740486-73-9 |
Cap-dependent-endonuclease-IN-14Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-14 has the potential for the research of viral infections caused by Influenza Viruses. |
|
2741952-35-0 |
Cap-dependent-endonuclease-IN-2Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus . |
|
2741952-36-1 |
Cap-dependent-endonuclease-IN-23Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A). |
|
2748522-40-7 |
Ketotifen-13C,d3 |
|
27591-97-5 |
TiloroneTilorone is a member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is a synthetic, small molecular weight compound that is an orally active interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist, used as an antiviral drug. Its hydrochloride salt is used as an antiviral drug. It has a role as an antiviral agent, an antineoplastic agent, and an anti-inflammatory agent. |
|
2759996-93-3 |
Tirfipiravir |
|
2760972-52-7 |
Antiviral agent 35 |
|
2779498-79-0 |
Mindeudesivir hydrobromide |
|
28302-36-5 |
Sodium copper chlorophyllin BSodium copper chlorophyllin B has antiviral activities against Influenza virus and HIV with IC50s of 50-100 μM. |
|
285978-13-4 |
Fmoc-Gly-OH-[13C2,15N]Fmoc-Gly-OH-2-[13C2,15N] is the labelled analogue of Fmoc-Gly-OH. Fmoc-Gly-OH is an N-Fmoc-protected form of Glycine. Glycine is one of the non-essential amino acids for humans. Glycine is an inhibitory neurotransmitter in the central nervous system. |
|
287383-59-9 |
ScriptaidScriptaid is an inhibitor of HDAC. It shows a greater effect on acetylated H4 than H3. |
|
2915761-74-7 |
RdRP-IN-5 |
|
2917502-08-8 |
Anti-Influenza agent 6 |
|
2919303-26-5 |
Influenza virus-IN-6 |
|
2928218-29-3 |
Umifenovir-d6 hydrochloride |
|
2935407-32-0 |
Neuraminidase-IN-18 |
|
2935407-34-2 |
Neuraminidase-IN-17 |
|
3010895-53-8 |
CYP2C19-IN-1CYP2C19-IN-1 is a selective inhibitor of the CYP2C19 enzyme, which is crucial for the metabolism of various medications, including antiplatelet drugs and proton pump inhibitors. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) with a Ki of 6.16 µM. By inhibiting CYP2C19, this compound can alter the metabolism and effectiveness of these drugs, potentially enhancing or prolonging their therapeutic effects and reducing the risk of adverse drug interactions. This inhibition is particularly relevant for optimizing treatments in patients who require precise drug dosing or are affected by variable drug metabolism. |
※ Please kindly note that our services are for research use only.